CN110612102A - 含有吡唑并喹啉衍生物的路易氏体病治疗剂 - Google Patents

含有吡唑并喹啉衍生物的路易氏体病治疗剂 Download PDF

Info

Publication number
CN110612102A
CN110612102A CN201880030146.7A CN201880030146A CN110612102A CN 110612102 A CN110612102 A CN 110612102A CN 201880030146 A CN201880030146 A CN 201880030146A CN 110612102 A CN110612102 A CN 110612102A
Authority
CN
China
Prior art keywords
dementia
disease
parkinson
lewy
test
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880030146.7A
Other languages
English (en)
Chinese (zh)
Inventor
宫本舞
石川幸雄
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanitary Material R&d Management Co ltd
Original Assignee
Sanitary Material R&d Management Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanitary Material R&d Management Co ltd filed Critical Sanitary Material R&d Management Co ltd
Publication of CN110612102A publication Critical patent/CN110612102A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201880030146.7A 2017-06-01 2018-05-30 含有吡唑并喹啉衍生物的路易氏体病治疗剂 Pending CN110612102A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762513727P 2017-06-01 2017-06-01
US62/513,727 2017-06-01
PCT/JP2018/020650 WO2018221551A1 (ja) 2017-06-01 2018-05-30 ピラゾロキノリン誘導体を含有するレビー小体病治療剤

Publications (1)

Publication Number Publication Date
CN110612102A true CN110612102A (zh) 2019-12-24

Family

ID=64456542

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880030146.7A Pending CN110612102A (zh) 2017-06-01 2018-05-30 含有吡唑并喹啉衍生物的路易氏体病治疗剂

Country Status (13)

Country Link
US (1) US11311530B2 (https=)
EP (1) EP3632438B1 (https=)
JP (1) JP7269875B2 (https=)
KR (1) KR20200010220A (https=)
CN (1) CN110612102A (https=)
AU (1) AU2018278422B2 (https=)
BR (1) BR112019023552A2 (https=)
CA (1) CA3061884A1 (https=)
ES (1) ES2961554T3 (https=)
IL (1) IL270357B2 (https=)
MX (1) MX394435B (https=)
TW (1) TWI784006B (https=)
WO (1) WO2018221551A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018221550A1 (ja) 2017-06-01 2018-12-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾロキノリン誘導体とメマンチンの併用による認知症治療剤
RU2019135834A (ru) 2017-06-01 2021-07-13 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Терапевтическое средство для лечения деменции, представляющее собой комбинацию производного пиразолохинолина и донепезила
KR20200010211A (ko) 2017-06-01 2020-01-30 에자이 알앤드디 매니지먼트 가부시키가이샤 Pde9 저해제를 포함하는 약제학적 조성물
WO2023064857A1 (en) 2021-10-14 2023-04-20 Incyte Corporation Quinoline compounds as inhibitors of kras

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100210839A1 (en) * 2002-08-23 2010-08-19 Boehringer Ingelheim International Gmbh Selective phosphodiesterase 9a inhibitors as medicaments for improving cognitive processes
CN103930423A (zh) * 2011-10-07 2014-07-16 卫材R&D管理有限公司 吡唑并喹啉衍生物
CN105121440A (zh) * 2013-04-05 2015-12-02 卫材R&D管理有限公司 吡唑并喹啉衍生物的盐及其晶体

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5318759A (en) 1976-08-02 1978-02-21 Nisshin Oil Mills Ltd Method of making fried beancurd
JPH05132484A (ja) 1991-04-26 1993-05-28 Otsuka Pharmaceut Factory Inc ピラゾロキノリン及びピラゾロナフチリジン誘導体
DK0760819T3 (da) 1994-05-24 2000-10-09 Hoffmann La Roche Tricykliske dicarbonylderivater
DE19642591A1 (de) 1996-10-15 1998-04-16 Basf Ag Neue Piperidin-Ketocarbonsäure-Derivate, deren Herstellung und Anwendung
HN2002000317A (es) 2001-11-02 2003-05-21 Pfizer Inhibidores de pde9 para tratamiento de trastornos cardiovasculares
BR0313262A (pt) 2002-08-07 2005-07-12 Mitsubishi Pharma Corp Compostos de dihidropirazolpiridina
DE102004004142A1 (de) 2003-05-09 2004-11-25 Bayer Healthcare Ag 6-Cyclylmethyl- und 6-Alkylmethyl-substituierte Pyrazolopyrimidine
RU2426734C2 (ru) 2003-10-03 2011-08-20 Зм Инновейтив Пропертиз Компани Пиразолопиридины и их аналоги
WO2005118583A1 (en) 2004-05-28 2005-12-15 Millennium Pharmaceuticals, Inc. 2, 5-dihydro-pyrazolo`4, 3-c!quinolin-4-ones as chk-1 inhibitors
JP2006045118A (ja) 2004-08-04 2006-02-16 Mochida Pharmaceut Co Ltd 新規ピラゾロキノロン誘導体
CA2622605A1 (en) 2005-09-15 2007-03-22 Aska Pharmaceutical Co., Ltd. Heterocycle compound, and production process and application thereof
CA2671980C (en) 2006-12-13 2015-05-05 Aska Pharmaceutical Co., Ltd. Quinoxaline derivatives
WO2008072778A1 (ja) 2006-12-13 2008-06-19 Aska Pharmaceutical Co., Ltd. 尿路系疾患の処置剤
PT2152712E (pt) 2007-05-11 2012-02-29 Pfizer Compostos amino-heterocíclicos
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
JP5453431B2 (ja) 2008-09-08 2014-03-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピラゾロピリミジン及びｃｎｓ障害の治療のためのそれらの使用
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物
WO2010101230A1 (ja) 2009-03-05 2010-09-10 アステラス製薬株式会社 キノキサリン化合物
PE20120505A1 (es) 2009-03-31 2012-05-09 Boehringer Ingelheim Int Derivados de 1-heterociclil-1,5-dihidro-pirazolo[3,4-d]pirimidin-4-ona como moduladores de pde9a
US8880976B2 (en) 2009-09-25 2014-11-04 Stmicroelectronics, Inc. Method and apparatus for encoding LBA information into the parity of a LDPC system
AP2012006631A0 (en) 2010-08-12 2012-12-31 Boehringer Ingelheim Int 6-Cycloalkyl-1, 5-dihydro-pyrazolo[3,4-D] pyrimidin-4-one derivatives and their use as PDE9A inhibitors
RS54834B1 (sr) 2010-09-07 2016-10-31 Astellas Pharma Inc Jedinjenja pirazolokvinolina
US20130040971A1 (en) 2011-02-14 2013-02-14 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders
PT2573073E (pt) 2011-09-26 2015-02-05 Sanofi Sa Derivados de pirazoloquinolinona, sua preparação e sua utilização terapêutica
JP6042060B2 (ja) 2011-09-26 2016-12-14 サノフイ ピラゾロキノリノン誘導体、その調製および治療上の使用
TW201439091A (zh) 2013-04-05 2014-10-16 Eisai R&D Man Co Ltd 吡啶基吡唑并喹啉化合物
KR20200010211A (ko) 2017-06-01 2020-01-30 에자이 알앤드디 매니지먼트 가부시키가이샤 Pde9 저해제를 포함하는 약제학적 조성물
RU2019135834A (ru) 2017-06-01 2021-07-13 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Терапевтическое средство для лечения деменции, представляющее собой комбинацию производного пиразолохинолина и донепезила
WO2018221550A1 (ja) 2017-06-01 2018-12-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾロキノリン誘導体とメマンチンの併用による認知症治療剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100210839A1 (en) * 2002-08-23 2010-08-19 Boehringer Ingelheim International Gmbh Selective phosphodiesterase 9a inhibitors as medicaments for improving cognitive processes
CN103930423A (zh) * 2011-10-07 2014-07-16 卫材R&D管理有限公司 吡唑并喹啉衍生物
CN105121440A (zh) * 2013-04-05 2015-12-02 卫材R&D管理有限公司 吡唑并喹啉衍生物的盐及其晶体

Also Published As

Publication number Publication date
ES2961554T3 (es) 2024-03-12
IL270357A (https=) 2020-02-27
BR112019023552A2 (pt) 2020-06-02
US11311530B2 (en) 2022-04-26
IL270357B2 (en) 2024-02-01
TW201902479A (zh) 2019-01-16
EP3632438B1 (en) 2023-08-23
JP7269875B2 (ja) 2023-05-09
AU2018278422B2 (en) 2022-03-17
MX394435B (es) 2025-03-12
RU2019135690A (ru) 2021-07-13
EP3632438A4 (en) 2020-12-23
MX2019013397A (es) 2020-02-07
AU2018278422A1 (en) 2019-11-21
WO2018221551A1 (ja) 2018-12-06
IL270357B1 (en) 2023-10-01
TWI784006B (zh) 2022-11-21
JPWO2018221551A1 (ja) 2020-04-02
KR20200010220A (ko) 2020-01-30
CA3061884A1 (en) 2019-10-29
RU2019135690A3 (https=) 2021-08-25
US20200155541A1 (en) 2020-05-21
EP3632438A1 (en) 2020-04-08

Similar Documents

Publication Publication Date Title
ES2586843T3 (es) Tratamiento de trastornos relacionados con BDNF usando laquinimod
EP3632439B1 (en) Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil
AU2018210145B2 (en) Use of pridopidine for the treatment of fragile X syndrome
CN117295710A (zh) Mdma对映异构体
KR102627790B1 (ko) 피라졸로퀴놀린 유도체와 메만틴을 병용한 치매 치료제
Anand et al. The animal models of dementia and Alzheimer’s disease for pre-clinical testing and clinical translation
JP7269875B2 (ja) ピラゾロキノリン誘導体を含有するレビー小体病治療剤
Chen et al. GABAA receptors in the central nucleus of the amygdala are involved in pain-and itch-related responses
JP2017534613A (ja) デクスメデトミジン製剤を使用する睡眠障害の予防または治療
EP3965769B1 (en) Use of 2-phenyl-6-(1h-imidazol-1-yl)quinazoline for treating neurodegenerative diseases, preferably alzheimer's disease
Nirogi et al. Usmarapride (SUVN-D4010), a 5-HT4 receptor partial agonist for the potential treatment of Alzheimer's disease: Behavioural, neurochemical and pharmacological profiling
Nazari-Serenjeh et al. Blocking the dopaminergic receptors within the hippocampal dentate gyrus reduced analgesic responses induced by restraint stress in the formalin test
WO2015060746A1 (ru) Комбинация для лечения и/или профилактики проявлений психических, когнитивных, поведенческих и неврологических нарушений при органических заболеваниях цнс различного генеза
BR112021005932A2 (pt) composição farmacêutica, combinação farmacêutica neuroprotetora, inibidor da acetilcolinesterase e agonista receptor de 5-ht4
Richter et al. The" campus syndrome" in pigs: neurological, neurophysiological, and neuropharmacological characterization of a new genetic animal model of high-frequency tremor
RU2802212C2 (ru) Терапевтическое средство для лечения болезни телец леви, содержащее производное пиразолохинолина
RU2784428C2 (ru) Терапевтическое средство для лечения деменции, представляющее собой комбинацию производного пиразолохинолина и мемантина
Forde Effects of MTEP, and oligomeric Aβ aggregates on spatial memory in rats

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination